Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: The previous standard treatment for chronic hepatitis C (CHC) patients, comprising a combination of pegylated interferon (IFN) and ribavirin, was associated with suboptimal efficacy and severe adverse reactions. A new era of direct-acting antivirals is now dawning in Korea. Early experience of applying sofosbuvir-based therapy to CHC patients in Korea is reported herein. Methods: Data on efficacy and safety were collected for CHC patients treated with a combination of sofosbuvir plus ribavirin or sofosbuvir/ledipasvir with or without ribavirin. Results: This retrospective study included 25 consecutive patients who received sofosbuvir-based therapy (19 with genotype 1b and 6 with genotype 2) at Seoul National University Hospital from May 2014 to April 2015. A virologic response was achieved at week 4 by 85.7% and 80% of the patients with genotypes 1b and 2, respectively. The HCV-RNA level decreased more slowly in IFN-experienced than in treatment-naїve patients with genotype 1b. However, the sustained virologic response at week 12 (SVR12) rate did not differ among these patients, and was as high as 100%. The presence of cirrhosis significantly increased the risk of a virologic response failure at week 4 (OR, 11.0; P=0.011) among patients with HCV genotype 1b. Only five patients (20%) experienced minor adverse events, including grade 1 fatigue and headache. The hemoglobin level decreased slightly after sofosbuvir-based therapy, but there was no case of premature discontinuation of this therapy. Conclusions: In a real clinical practice, sofosbuvir-based therapy for CHC patients in Korea achieved optimal antiviral efficacy with insignificant adverse events. Long-term follow-up data are warranted to ensure the sustained antiviral efficacy and long-term safety of sofosbuvir-based IFN-free therapy.
Abstract
Background/Aims: The previous standard treatment for chronic hepatitis C (CHC) patients, comprising a combination of pegylated interferon (IFN) and ribavirin, was associated with suboptimal efficacy and severe adverse reactions. A new era of direct-acting antivirals is now dawning in Korea. Early experience of applying sofosbuvir-based therapy to CHC patients in Korea is reported herein. Methods: Data on efficacy and safety were collected for CHC patients treated with a combination of sofosbuvir plus ribavirin or sofosbuvir/ledipasvir with or without ribavirin. Results: This retrospective study included 25 consecutive patients who received sofosbuvir-based therapy (19 with genotype 1b and 6 with genotype 2) at Seoul National University Hospital from May 2014 to April 2015. A virologic response was achieved at week 4 by 85.7% and 80% of the patients with genotypes 1b and 2, respectively. The HCV-RNA level decreased more slowly in IFN-experienced than in treatment-naїve patients with genotype 1b. However, the sustained virologic response at week 12 (SVR12) rate did not differ among these patients, and was as high as 100%. The presence of cirrhosis significantly increased the risk of a virologic response failure at week 4 (OR, 11.0; P=0.011) among patients with HCV genotype 1b. Only five patients (20%) experienced minor adverse events, including grade 1 fatigue and headache. The hemoglobin level decreased slightly after sofosbuvir-based therapy, but there was no case of premature discontinuation of this therapy. Conclusions: In a real clinical practice, sofosbuvir-based therapy for CHC patients in Korea achieved optimal antiviral efficacy with insignificant adverse events. Long-term follow-up data are warranted to ensure the sustained antiviral efficacy and long-term safety of sofosbuvir-based IFN-free therapy.
참고문헌 (32)
- Ghany MG, "Diagnosis, management, and treatment of hepatitis C: an update", Hepatology, 49, pp.1335~1374 (2009)
- Shiffman ML, "Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3", N Engl J Med, 357, pp.124~134 (2007)
- Fried MW, "Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection", N Engl J Med, 347, pp.975~982 (2002)
- Sulkowski MS, "Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C", Nat Rev Gastroenterol Hepatol, 8, pp.212~223 (2011)
- Falck-Ytter Y, "Surprisingly small effect of antiviral treatment in patients with hepatitis C", Ann Intern Med, 136, pp.288~292 (2002)
- Lam AM, "PSI-7851, a pronucleotide of beta-D-2’-deoxy-2’-fluoro-2’-Cmethyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication", Antimicrob Agents Chemother, 54, pp.3187~3196 (2010)
- Panel AIHG., "Hepatitis C Guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C Virus", Hepatology, 62, pp.932~954 (2015)
- European Association for Study of L, "EASL Recommendations on Treatment of Hepatitis C 2015", J Hepatol, 63, pp.199~236 (2015)
- Lawitz EJ, "A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C", J Hepatol, 57, pp.24~31 (2012)
- Gane EJ, "Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C", N Engl J Med, 368, pp.34~44 (2013)
- Hagan LM, "Cost analysis of sofosbuvir", ribavirin versus sofosbuvir, intolerant individuals, pp.Hepatology, 2014[DOI]
- European Association for the Study of the Liver, "Electronic address eee. EASL Recommendations on Treatment of Hepatitis C 2015", J Hepatol, 63, pp.199~236 (2015)
- Kowdley KV, "Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis", N Engl J Med, 370, pp.1879~1888 (2014)
- Jacobson IM, "Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options", N Engl J Med, 368, pp.1867~1877 (2013)
- Castera L, "Non-invasive evaluation of liver fibrosis using transient elastography", J Hepatol, 48, pp.835~847 (2008)
- Bacon BR, "Boceprevir for previously treated chronic HCV genotype 1infection", N Engl J Med, 364, pp.1207~1217 (2011)
- Bourliere M, "Future treatment of patients with HCV cirrhosis", Liver Int, 32(1), pp.113~119 (2012)
- Jacobson IM, "Telaprevir for previously untreated chronic hepatitis C virus infection", N Engl J Med, 364, pp.2405~2416 (2011)
- Poordad F, "Boceprevir for untreated chronic HCV genotype 1 infection", N Engl J Med, 364, pp.1195~1206 (2011)
- Sherman KE, "Response-guided telaprevir combination treatment for hepatitis C virus infection", N Engl J Med, 365, pp.1014~1024 (2011)
- Vierling JM, "Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon", ribavirin, including prior null response, 2014, pp.60, 748~756
- Colombo M, "Safety and on-treatment efficacy of telaprevir : the early access programme for patients with advanced hepatitis C", Gut, 63, pp.1150~1158 (2014)
- Hezode C, "Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme(ANRS CO20-CUPIC)-NCT01514890", J Hepatol, 59, pp.434~441 (2013)
- Ghany MG, "An update on treatment of genotype 1 chronic hepatitis C virus infection : 2011 practice guideline by the American Association for the Study of Liver Diseases", Hepatology, 54, pp.1433~1444 (2011)
- Afdhal N, "Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection", N Engl J Med, 370, pp.1889~1898 (2014)
- Medeiros-Filho JE, "Differences in viral kinetics between genotypes 1 and 3 of hepatitis C virus and between cirrhotic and non-cirrhotic patients during antiviral therapy", World J Gastroenterol, 12, pp.7271~7277 (2006)
- Afdhal NH, "Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy", Gastroenterology, 146, pp.442~452 (2014)
- Poordad F, "Exploratory study of oral combination antiviral therapy for hepatitis C", N Engl J Med, 368, pp.45~53 (2013)
- Lok AS, "Preliminary study of two antiviral agents for hepatitis C genotype1", N Engl J Med, 366, pp.216~224 (2012)
- Gane EJ, "Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial", Lancet, 376, pp.1467~1475 (2010)
- Chayama K, "Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders", Hepatology, 55, pp.742~748 (2012)
- Lawitz E, "A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450", r, ABT-072) and ribavirin in IL28B C, J Hepatol, pp.2013, 59[DOI]